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Abstract: Bowen’s disease (squamous cell carcinoma in situ) has a 3%–5% risk to develop 
into invasive squamous cell carcinoma. Non-melanoma skin cancer is the most common cancer 
among Caucasians and its incidence has increased during the last decades dramatically. Multiple 
treatment options for Bowen’s disease have been described and are established with advantages 
and disadvantages. Bowen’s disease occurs more often in elderly patients (with a higher risk 
of comorbidities) and is frequently located on body sites with poor wound healing. Therefore 
there is need for non-invasive/non-destructive but effective treatment options.
We would like to give an overview of established therapies and more detailed information 
about the newer treatment options for Bowen’s disease with topical diclofenac, topical imiquimod 
and photodynamic therapy.
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Introduction
Bowen’s disease (BD) is an in situ squamous cell carcinoma (SCC) which was ﬁ  rst 
described in 1912 by JT Bowen.
Clinically a typical BD is a slowly enlarging erythematous patch or plaque which is 
well demarcated and has a scaling or crusted surface. In some cases it can be pigmented 
or verrucous. It is commonly located on the lower limbs and on the head and neck. But 
BD is also seen subungual or periungual, palmar, genital and perianal. Usually BD 
is a solitary lesion, but in 10% to 20% it occurs at multiple sites (Thestrup-Pedersen 
et al 1988; Cox et al 2007). The risk of progression into an invasive carcinoma is 3% 
to 5% in extragenital lesions and about 10% in genital lesions (Kao 1986; Cox et al 
1999). BD is very common in the Caucasian population with an incidence of 1.42 per 
1000 in some populations (Reizner et al 1994).
Several etiological factors of BD have been reported, such as irradiation (ultraviolet 
irradiation, radiotherapy, photochemotherapy), carcinogens (eg, arsenic), immunosuppression 
(eg, after organ transplantation, AIDS), viral (strong association of perianal and genital 
lesions with HPV; 47% of acral and 24% of nonacral extragenital BD contain HPV genome) 
and some others like chronic injury or dermatoses (Clavel et al 1999; Cox et al 2007).
Treatment options for Bowen’s disease
Efﬁ  cacy comparison and evaluation of different treatment options and treatment studies 
of Bowen’s disease are difﬁ  cult because there is a variety of different protocols and the 
success of a treatment modality is dependent on several factors (eg, body site, lesion 
size and thickness, different equipment).
The choice of treatment should be guided by efﬁ  cacy, location and size of BD, 
number of lesions, availability of the therapy, the clinician’s expertise, patient factors 
(age, immune status, concomitant medication, comorbidities and compliance), cosmetic 
outcome and the patient’s preference.Therapeutics and Clinical Risk Management 2008:4(5) 1086
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The different treatment options for BD are cryotherapy, 
curettage with cautery, excision, 5-ﬂ  uorouracil (5-FU), 
radiotherapy, laser, photodynamic therapy (PDT), imiqui-
mod and some other therapies that were described in some 
case reports or small numbers of patients. Up to now none 
of the treatment options has been unequivocally proven to 
be superior to any other.
This paper is focused on the newer treatment options for 
BD: topical diclofenac and imiquimod and photodynamic 
therapy.
Cryotherapy
The clearance and recurrence rates of cryotherapy vary 
between different studies. The reasons for this variety of 
results are different techniques and regimens (especially 
freezing time and number of freeze-thaw cycles (FTC)), 
lesion size and location of BD. In a retrospective study a 
clinical clearance of 61% was achieved (Bell and Rhodes 
1999). Excellent results in combination with low recurrence 
rates were described for 30s freeze-thaw cycle liquid 
nitrogen cryotherapy (Plaza de Lanza et al 1980; Holt 
1988). Lower recurrence rates were achieved by longer and 
repeated freezing cycles whereby problems like prolonged 
wound healing and poor cosmetic outcome (scaring, 
hypopigmentation) increased (Plaza de Lanza et al 1980; Holt 
1988; Cox and Dyson 1995; Ball and Dawber 1998).
In comparative studies cryotherapy showed clearance 
rates from 50% to 100% by one to three 20s freeze-thaw 
cycles and recurrence rates from 10% (one 20s FTC, fol-
low up 12 months) up to 36% (two 5 to 10s FTC, follow 
up 24 months) (Morton et al 1996; Ahmed et al 2000). 
Wound healing was faster with cryotherapy compared to 
radiotherapy, but slower than curettage and cautery regimen 
(Cox and Dyson 1995; Ahmed et al 2000). In comparison 
with PDT after cryotherapy ulceration was seen in 25% of 
the treated lesions (no ulceration in the PDT group) and the 
clearance rate of a single PDT was signiﬁ  cantly higher than 
one 20s FTC (Morton et al 1996).
In conclusion cryotherapy with liquid nitrogen is an 
effective, commonly used option in the treatment of BD 
entailing only low costs. Especially for single and small 
BD located in well healing sites cryotherapy is a favorable 
treatment option.
Curettage with cautery
The reported cure rates and recurrence rates of this method 
differ due to different regimes, equipment used and skill of the 
clinician. Cure rates ranged from 81% for curettage up to 93% 
to 98% for curettage and cautery with a follow up of 2.5 to 
4 years (Honeycutt and Jansen 1973; Thestrup-Pedersen 
et al 1988; Morton al 1996). In a comparative study with a 
follow up of 2 years there was a recurrence in the curettage 
and cautery group in 4 of 44 lesions and in the cryotherapy 
group (two 5 to 10 s FTC) in 13 of 36 lesions (Ahmed et al 
2000). In this study curettage and cautery was associated 
with a better and faster wound healing, less discomfort and 
pain and a lower rate of complications. Additional anecdotal 
reports described a therapy regime that combined curettage 
and cryotherapy (Nordin 1999).
In summary curettage and cautery is a safe and effective 
therapy of BD with a very good cost-beneﬁ  t analysis. It is 
suitable especially for small single BD.
Excision
Up to now no randomized, comparative studies have been 
published for surgery of BD. In 2 retrospective studies 
recurrence rates ranged from 4.6% up to 19% (Graham and 
Helwig 1961; Thestrup-Pedersen et al 1988). Higher rates 
were reported for perianal BD. Mohs micrographic surgery 
is especially performed in sites of the body where tissue-
sparing surgery is necessary (eg, ﬁ  ngers and nail unit, penis). 
The recurrence rates differed from 6.3% up to 21%–28% 
(follow up 1 to 5 years) due to different body sites, viral 
etiology, large wound defects and lesion size. Perianal BD 
showed in a retrospective study of 47 cases a recurrence 
rate for wide excision of 23%, for local excision 53% and 
for laser therapy 80% (treatment with radiotherapy was not 
included)(Marchesa et al 1997). The most frequently used 
therapy for perianal BD is wide excision and the surgical 
treatment has been advocated as the treatment of choice 
(Cleary et al 2000; Cox et al 2007).
In conclusion surgical excision of BD is one of the 
standard treatments especially for small and single, digital 
and perianal BD. The main advantage is the securing of 
histological free excision margins. Possible limitations are 
cosmetic and functional outcome and prolonged or compli-
cated wound healing in some body areas.
Fluorouracil
For the treatment with topical 5-FU the reported clearance 
and cure rates showed a wide range due to the use of different 
therapy regimens and concentrations. The commercially 
available and in most studies used concentration is a 5% 
5-FU preparation. Once or twice daily application for vari-
able periods of time (1 week to 2 months or even longer) 
is described, with preference for the twice daily usage and Therapeutics and Clinical Risk Management 2008:4(5) 1087
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longer treatment periods (8 weeks) with clearance rates up 
to 92% (Bargmann and Hochmann 2003).
Pulse therapies with 5-FU have been reported with a 
limited evidence base. A randomized trial for the treatment of 
BD with either PDT or 5-FU (1 or if required 2 cycles of once 
daily application for 1 week and twice daily for week 2–4) 
reported an initial clinical clearance for PDT in 88% and for 
5-FU in 67%, with a clearance rate at follow up (12 months) 
of 82% (PDT) and 48% (5-FU) (Salim et al 2003).
Increasing effectiveness has been reported when 5-FU was 
combined with other therapeutic modalities like occlusive 
application, iontophoresis, pretreatment with erbium:YAG 
laser, cryotherapy, imiquimod and acitretin with response 
rates up to 96,2% (Heising 1979; Welch et al 1997; Khandpur 
and Sharma 2003; Wang et al 2004). The advantage of 5-FU 
cream is that it can be easily applied by the patients them-
selves accompanied by frequent clinical controls. The therapy 
with 5-FU is limited by local inﬂ  ammation with erosion and 
ulceration which may last for several weeks.
In summary the commercially available 5% 5-FU prepa-
ration has shown its efﬁ  cacy in short- and long-term studies 
and can be used for the treatment of BD in good or even bad 
healing sites and for special sites like ﬁ  ngers or penis.
Radiotherapy
Different radiotherapy techniques (external beam 
radiotherapy, Grenz rays, radioactive skin patches) have 
been used in the treatment of BD with reported cure rates 
between 94% and 100% (Stevens et al 1977; Lee et al 
1997; Turpin 1999; Chung et al 2000; Lukas VanderSpek 
et al 2005). For BD located at poor healing sites (especially 
lower leg) radiotherapy should be avoided due to poor 
healing/failure-to-heal rates in 20% to 25 % of treated lesions 
(Cox and Dyson 1995; Dupree et al 2001). Severe toxicity 
of radiotherapy (eg, cartilage/bone necrosis) was reported 
for hypofractionated regimens after treatment of BD of the 
extremities (Lukas VanderSpek et al 2005).
To avoid some of the disadvantages and adverse effects 
of conventional radiotherapy skin patches equipped with 
the β-emitter holmium-166 were designed for the treatment 
of BD and other skin cancers (Lee et al 1997; Turpin 1999; 
Chung et al 2000). In 29 biopsy-conﬁ  rmed BD histological 
clearance was reported at 5 month without any recurrence after 
10–24 month (Chung et al 2000). In this study the functional 
and cosmetic outcome was good with no serious adverse effects 
(only desquamation, erythema and erosion were seen).
For anal/perianal BD radiotherapy has been reported as 
a reasonable treatment of choice particularly when other 
therapies (eg, surgery) are difﬁ  cult to carry out (Cox et al 
1999; Papillon and Chassard 1992; Lukas VanderSpek et al 
2005. But there is no strong evidence supporting this point 
of view.
In conclusion radiotherapy should not be used for poor 
healing sites (especially not for the lower leg) but it can be an 
alternative with high efﬁ  cacy when other treatment options 
(eg, surgery) are difﬁ  cult or not possible (eg, very old patients 
with comorbidities and medication with anticoagulants, 
special sites like perianal or penile BD).
Laser
So far no randomized controlled trials to evaluate laser 
therapy in BD have been reported. The published data result 
from case reports and small series. Argon, CO2 and Nd:YAG 
laser have been used for the treatment of BD.
Complete response of BD of the digits by CO2 laser 
with no recurrence in the 0.5 to 7.7 years follow up was 
published in some studies with good functional and cosmetic 
outcome (Gordon et al 1994; Gordon et al 1996; Tantikun 
2000), although others reported some failures (1 of 5 digi-
tal lesions) (Gordon et al 1994) or progression to invasive 
SCC of lower leg lesions after 100% healing at 2 months 
and complete response at 6 months (3/16 patients) (Dave 
et al 2003). Genital lesions showed complete response after 
treatment with argon, CO2 and Nd:YAG laser (Landthaler 
et al 1986) with more recent data that reported a recurrence 
rate of 26% (van Bezooijen et al 2001). For perianal BD 
the results of laser therapy were poor (Cleary et al 2000), 
although a case report showed a clearance and no recurrence 
within 14 month after treatment with argon laser (Boynton 
and Bjorkman 1991).
In summary especially the CO2 laser can be used for penile 
or digital BD with only limited data of recurrence rates.
Other therapies
As some of the most standard therapies for BD mentioned 
above are not evaluated by controlled randomized trials, 
data of other less commonly used therapies result from case 
reports or only small numbers of patients.
Local hyperthermia was tried by the use of chemical 
pocket warmers applied on the lesions under pressure with 
initial complete clinical clearance in six of eight patients 
but with histological clearance in only three of eight cases 
(Hiruma and Kawada 2000).
In 20 BD lesions (large and lower leg lesions included) 
an ultrasonic surgical aspirator was used with no recurrence 
during the follow up (12 to 26 months, mean 20 months) Therapeutics and Clinical Risk Management 2008:4(5) 1088
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(Otani et al 2001). After 10 months acitretin therapy in one of 
the two treated patients 90% of the multiple lesions cleared. 
The other patient did not tolerate the acitretin and no improve-
ment was seen (Yerebakan et al 2002). In other reports for 
example, the use of topical (in combination with liquid 
nitrogen) and intralesional bleomycin (Dyall-Smith 1998; 
Ota et al 2002) and oral isotretinoin in combination with 
subcutaneous interferon-α (1 patient treated for 3 months for 
multiple BD, no recurrence 15 month after therapy) (Gordon 
et al 1997) was reported.
Newer treatment options
Diclofenac
Diclofenac inhibits cyclooxygenase enzymes and thereby 
downstream byproducts of arachidonic acid (AA) 
metabolism are decreased. In the promotion of epithelial 
tumor growth these metabolites of AA have shown to play 
an essential role by several mechanisms and pathways 
(eg, inhibition of apoptosis and immune surveillance, 
stimulation of angiogenesis, etc) (Gately 2000; Masferrer 
et al 2000).
Diclofenac 3% gel has been successfully used in the 
treatment of actinic keratosis (Wolf et al 2001; Smith et al 
2006). Two cases of BD were treated with 3% diclofenac 
gel twice daily for 80 to 90 days with no residual disease 
clinically and histologically (Dawe et al 2005).
In another series of 5 patients the biopsy proven BD 
were treated once daily with diclofenac 3% gel for 8 weeks. 
The treatment was well tolerated with mild inﬂ  ammation 
after 6 weeks and mild side effects like itching and dryness. 
Complete clinical and histological clearance was proven by 
biopsies taken 4 weeks after end of treatment (Pantel and 
Stockﬂ  eth 2007).
However these promising data have to be proven in 
randomized controlled trials and optimum regimens (eg, 
once vs twice daily application, duration of application) 
and recurrence rates in long-term follow-up have to be 
investigated.
Imiquimod
Imiquimod 5% cream is a topical immune response modiﬁ  er 
with approval in most pharmaceutical markets for the treat-
ment of anogenital warts, actinic keratoses and superﬁ  cial 
basal cell carcinoma.
Imiquimod is heterocyclic imidazoquinoline amid with 
antiviral and antitumor effects. Imiquimod itself does not 
have antiviral or antiproliferative abilities, its efﬁ  cacy is 
ascribed to the stimulation of innate and acquired immunity. 
Binding of imiquimod to toll-like receptor(TLR)-7 and -8 
induces production of cytokines like interferon (IFN) alfa, 
tumor necrosis factor alfa, interleukin (IL)-1α, IL-1 recep-
tor antagonist, IL-12 and IFN-γ resulting in a T-lymphocyte 
helper type 1 coordinated cell mediated immunity (Hengge 
et al 2001; Temmi et al 2002). During partial regression of 
BD a T-lymphocyte-rich inﬁ  ltrate was seen in the dermis 
with epidermal apoptosis (Habetts et al 1989; Murata et al 
1996). Furthermore resolution of BD was observed after 
treatments promoting cell-mediated immunity and apoptosis 
(Raaf et al 1967; Gordon et al 1997). Topical application on 
the skin results in a keratinocyte secretion of IL-6, Il-8, and 
IFN-α. The antiviral effects of imiquimod are mediated by 
IFN-α. IFN-α induces proteins that activate RNAses and are 
pivotal for antiviral activity. Furthermore Imiquimod induces 
maturation of Langerhans cells and migration to the regional 
lymph nodes and an increase of antigen presentation. Imiqui-
mod has indirect effects on T-cells and T-cell cytokines (eg, 
IL-2, IL-4, IL-5) by the induction of IFN-γ that results in a 
production of these cytokines in peripheral mononuclear 
cells. These cytokines again increase cell-mediated immune 
responses. Imiquimod is able to induce antigen speciﬁ  c 
B-lymphocytes. Proliferation of B-cells is increased and the 
expression of MHC class II and B7.2 that are important for 
antigen presentation (Meykadeh and Hengge 2003).
Recently it has been reported that imiquimod can directly 
induce apoptosis in SCC cell lines, independently of inﬂ  am-
matory cells (Schön et al 2003). In this apoptotic reaction a 
cytosolic translocation of mitochondrial membrane protein 
cytochrome c by a Bcl-2-dependent pathway was observed. 
In the treatment of basal cell carcinoma with imiquimod this 
Bcl-2-depletion and a higher rate of apoptotic keratinocytes 
were seen (Urosevic et al 2003; Vidal et al 2004).
In a phase II open label study (16 patients with BD treated 
with imiquimod) the CD4/CD8 lymphocyte ratio in pre- and 
post-treatment biopsy specimens reversed from 2:1 to 1:2.2, 
indicating a recruitment of CD8+ T lymphocytes (cytotoxic/
suppressor T lymphocytes) in the lesion (Mackenzie-Wood 
et al 2001). In this study 16 BD (15 located an the legs, with 
6 on the shin and one on the shoulder; maximum diameter 
1 to 5.4 cm) were treated once daily up to 16 weeks 
(10 patients 16 weeks, 6 patients 4 to 8 weeks because of 
local side effects) with 93% (14 of 15 patients who completed 
the study) clinical and histological clearance. Local skin 
reactions appeared in 15 of the 16 patients. 6 patients 
stopped the treatment after 4–8 weeks due to marked skin 
reactions like superﬁ  cial erosions with hemorrhagic crusts. 
All of these areas healed within 6 weeks after treatment Therapeutics and Clinical Risk Management 2008:4(5) 1089
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was stopped. In 4 other patients the treatment site healed 
without any residual crusting, although the treatment was 
not discontinued during the 16 weeks. In another 3 patients 
the treatment was discontinued for 6 to 13 days because of 
local reactions, but after the rest periods they completed the 
treatment without any ﬂ  are up. In most of the patients the 
surrounding normal skin was not affected, but in patients 
with chronic sun damage satellite reactions were seen. During 
the study no remarkable changes in laboratory tests and no 
systemic side effects were seen.
In a randomized, double-blind, placebo-controlled trial 
(daily placebo/imiquimod for 16 weeks) 9 of 12 (75%) (11 of 
15 resolved as per intention-to-treat analysis) patients in 
the imiquimod group and none in the placebo group had 
complete clearance of BD with no recurrence during 
the 9 months follow up. Three patients dropped out (1 was 
lost to follow-up, 1 patient with chronic photodamage had 
extended marked inﬂ  ammatory reaction and a third patient 
had a localized Staphylococcus aureus infection, resolving 
after oral antibiotic therapy and stopping the imiquimod 
treatment). The local side effects (mild itching-edema with 
erosion) were similar to other studies (Patel et al 2006).
In another randomized, double-blind, placebo-controlled 
trial in high risk renal transplant recipients in the verum 
group imiquimod 5% cream was applied 3 times per week 
for 16 weeks with reduction of skin atypia in 7 of 14 cases 
(placebo group 1 of 6 cases) and a lower frequency of 
squamous skin tumors (Brown et al 2005).
Alternative regimens (application of imiquimod 5% 
cream 2 to 3 times per week for 6 weeks) with 87% clinical 
clearance (Sierra-Valenti 2003) and cyclic application 
(application of imiquimod 5% cream 3 times per week for 
3 weeks, rest period of 4 weeks, second cycle if necessary) 
with maintaining good results (Chen and Shumack 2003) 
were assessed with a clear reduction of side effects and a 
better acceptance.
In a small series with 3 patients imiquimod 5% cream was 
applied occlusive with a 30% reduction of treatment duration 
but with systemic side effects like fever, ﬂ  u-like symptoms, 
and psychic depression (suggesting signiﬁ  cant imiquimod 
absorption under occlusion) (Muzio et al 2004).
Imiquimod 5% cream was used in combination with 
5-ﬂ  uorouracil in kidney transplant recipients (Smith et al 
2001) and in combination with sulindac (COX-2 inhibitor) 
in immunosuppressed patients with chronic lymphocytic 
leukemia (Smith et al 2001).
In addition to the randomized, double-blind, placebo-
controlled trial in high risk renal transplant recipients treated 
with 5% imiquimod cream and the combined therapy regimen 
(imiquimod and 5-FU) mentioned above, other publications 
showed efficacy of imiquimod 5% cream in transplant 
patients as well (Stockﬂ  eth et al 2003; Prinz et al 2004).
In other case reports successful treatment of genital 
BD/erythroplasia of Queyrat (Cook-Bolden and Weinberg 
2002; Orengo et 2002; Schroeder and Sengelmann 2002; 
Thai and Sinclair 2002; Arlette 2003; Danielsen et al 2003; 
Mandekou-Lefaki et al 2003; Micali et al 2003), anal/perianal 
BD (Phoushek and Smith 2001; Gutzmer et al 2002; Kreuter 
et al 2004), large facial BD (Kossard 2003), and BD of the 
eyelid (Brannan et al 2005) was shown with good functional 
and cosmetic outcome.
Despite these good results, 2 cases have been published 
in which invasive SCC developed after the treatment of BD 
with imiquimod (Goh 2006).
A summarized overview of studies and some case reports 
is given in Table 1.
In conclusion topical imiquimod 5% cream is an effective 
alternative treatment option for patients and body sites that 
are unsuitable for other treatments like surgery. Nevertheless 
further large randomized, double-blind controlled-
prospective studies with long-term follow-up are required 
to verify the results mentioned above and to ﬁ  gure out an 
optimal dosing scheme (duration of treatment, number of 
weekly applications) with high efﬁ  cacy and decreased local 
side effects and an optimal cost-to-beneﬁ  t analysis.
Photodynamic therapy
Photodynamic therapy (PDT) is a well established therapeutic 
option for actinic keratoses, basal cell carcinoma (superﬁ  cial 
and nodular) and BD (Braathen et al 2007).
PDT is based on the combination of light and light 
sensitive agents (eg, porphyrins) in the presence of oxygen. 
The energy of photons is absorbed by porphyrins and then 
transferred to surrounding oxygen molecules. The formation 
of cytotoxic oxygen species (eg, singulet oxygen) and free 
radicals results in cell death (Szeimies et al 1995). Exact 
mechanisms of topical PDT in NMSC at cellular level are 
not completely known but apoptosis (Noodt et al 1996; 
Webber et al 1996; Gad et al 2001; Kuzelova et al 2004) 
as well as necrosis (Noodt et al 1996) have been described 
after PDT.
Currently used topical photosensitizer precursors are 
5-aminolevulinic acid (ALA) and methyl aminolevulinate 
(MAL). MAL-PDT is approved for the treatment of BD 
in 22 European countries. After topical application and 
accumulation in neoplastic lesions ALA and MAL are Therapeutics and Clinical Risk Management 2008:4(5) 1090
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converted into photoactive porphyrins (protoporphyrin IX) 
with a higher selectivity for neoplastic lesions with MAL 
(Fritsch et al 1998; Sorensen et al 1998; Peng et al 2001). 
For the production and accumulation of these photoactive 
porphyins a sufﬁ  cient period of time is necessary before the 
light activation (for MAL 3 hours, for ALA 4 hours up to 
14 to 18 hours were stipulated by some authors) (Braathen 
et al 2007). With MAL-PDT no signiﬁ  cant systemic uptake 
was detected (Sorensen et al 1998).
The light sources used for PDT should match one of the 
absorption peaks of the photoactive porphyrins. Visible blue 
light (405 nm), green light (540 nm) and red light (630 nm) 
from different light sources are used for PDT with a deeper 
light penetration in the skin for longer wavelengths. In a 
randomized comparison study red light was more effective 
than green light for ALA-PDT of BD (initial clearance 94% vs 
72%, 12 month clearance 88% vs 48%) (Morton et al 2000).
Several studies provided evidence for the use of topical 
PDT in BD (summarized overview in Table 2) with initial 
clearance rates between 88% and 100% (Morton et al 1996; 
Morton et al 2000; Salim et al 2003).
The reported recurrence rates after 12 months were 15% 
for MAL-PDT (cryotherapy 21%, 5-FU 17%) (Morton et al 
2004) and 0%–12% for ALA (cryotherapy 10%, 5-FU 18%) 
(Morton et al 1996; Morton et al 2000; Salim et al 2003). 
Reports about long-term clearance rates are rare. In a 
retrospective study (617 patients with BD) the recurrence rates 
after more than 5 years were 5% for surgery, 6% for radiother-
apy, 14% for 5-FU, 19% for curettage and 34% for cryotherapy 
(Thestrup-Pedersen et al 1988). For PDT a relapse rate of 17% 
after 64 months was reported (Leman et al 2002) suggesting 
a comparable long-term efﬁ  cacy of PDT and other established 
treatment options.
In the largest randomized, placebo-controlled, multicenter 
study the initial cure was 93% for MAL-PDT (5-FU 83%, 
cryotherapy 86%, 21% placebo-PDT) (Morton et al 2004). 
At the 24 months follow-up the complete response rate was 
68% (5-FU 59%, cryotherapy 60%, 11% placebo-PDT). In 
this trial the percentage of an excellent or good cosmetic 
outcome at 3 months was 89% in the PDT group (cryotherapy 
47%, 5-FU 76%) with an improvement after 12 month to 97% 
for PDT (cryotherpy 62%, 5-FU 94%). The tolerability of 
MAL-PDT was excellent and superior to cryotherapy and 
5-FU (pain was experienced by most PDT patients, but the 
degree was less than in the cryotherapy group; 5-FU had a poor 
local tolerability because of eczematous reactions, erosion 
and ulceration) (Morton et al 2004). In the patients treated 
with MAL-PDT no serious adverse events were seen (in the 
cryotherapy group two therapy-related adverse events were 
reported: lymphangitis and necrosis).
Table 1 Summary of reviewed studies and case reports on topical imiquimod
Reference Treatment groups Number 
of lesions
Regimen Results (at 
last follow-up)
Follow-up Notes




Imiquimod 5% once 
daily for 16 weeks
75% (9/12)
0% CR
9 months 3 drop outs in the 
imiquimod group
Mackenzie-Wood et al Imiquimod 16 Imiquimod 5% once 
daily for 16 weeks
93% CR (13/14) 6 months 2 patients died from 
unrelated illness
Smith et al Imiquimod 5% + 5-FU 5 Alternating Imiquimod 
3 × and 5-FU 4 × per 
week for 5–7 weeks
100% CR 3–15 months Renal transplant recipients
Smith et al Imiquimod 5% + sulin-
dac + valacyclovir
5 Imiquimod 5% 
3 ×/week + sulindac 
200 mg 2 ×/d + 
valacyclovir 1000 mg/d 
for 16 weeks
100% CR 5–14 months Patients with chronic 
lymphatic leukemia
Muzio et al Imiquimod 5% 3 Imiquimod 5% under 
occlusive dressing 
(changed every 3 days) 
for 60–75 days
100% CR 267–423 days Systemic side effects
in 2 patients
Prinz et al Imiquimod 5% 4 Imiquimod 5% 
3 ×/week (daily 
application in case 
of no clinical response 
after 2 weeks)
75% CR (3/4) 6 months Organ transplant 
recipients; 1 recurrence 
after 10 months
Abbreviations: CR, complete response; FU, 5-ﬂ  uorouracil.Therapeutics and Clinical Risk Management 2008:4(5) 1091
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Also in other comparative studies ALA-PDT was superior 
in efﬁ  cacy with less adverse events compared with 5-FU 
(Salim et al 2003) and less painful compared to cryotherapy 
(Morton et al 1996; Ahmed et al 2000).
Successful treatment of digital BD with PDT was reported 
with good functional and cosmetic results (complete response 
in 4/4 patients with follow-up of 16 month, 1 recurrence 
after 8 months responding to retreatment (Wong et al 2001); 
complete response in 1/1 patient during 30 months follow-up 
(Usmani et al 2005).
In 2 cases after the treatment of anogenital BD with PDT 
a progression to SCC was reported (in both cases other treat-
ments were performed either before or after the PDT) (Varma 
et al 2000; Heart et al 2006).
In immunosuppressed transplant recipients MAL-PDT was 
compared with 5-FU with complete resolution in 89% (8/9) 
after PDT and 13% in the 5-FU group (follow-up 6 months) 
(Perrett et al 2006). In another open trial ALA-PDT in 
immunosuppressed transplant recipients was compared with 
ALA-PDT in immunocompetent patients in the treatment 
of AK and BD. The four BD in the transplant recipients 
cleared 1 month after treatment with 2 recurrences during 
the follow-up (48 months) (Dragieva et al 2004).
In summary topical PDT in the treatment of BD is 
a therapy option with high efﬁ  cacy and good cosmetic 
outcome. It is tissue-sparing and non-invasive and especially 
suited for poor-healing sites, patients with large and multiple 
lesions and patients with comorbidities (eg, diabetes, immu-
nosupression, treatment with anticoagulants). The side effects 
(predominantly local phototoxic effects like burning, sting-
ing and prickling sensations and pain) are mild-moderate, 
of short duration and easily managed. Rare side effects are 
erosions, ulceration, blisters, pustules, peeling, and hyper- or 
hypopigmentation (DeHaas al 2007). Topical PDT has been 
recommended as a ﬁ  rst-line therapy for BD or even the best 
treatment option of BD (Salim et al 2003; Braathen et al 
2007; Lehmann 2007).
In immunosuppressed transplant recipients (more than 
one million patients worldwide) with an incidence of 
cutaneous premalignant and malignant lesions from 40% to 
60% after 20 years (Boyle et al 1984) and sometimes more 
than 100 NMSC in high risk patients with fatal outcome in 
10% (Berg and Otley 2002) topical PDT is particularly useful 
because large areas can be treated and the treatment can 
and should be repeated frequently. Although the long-term 
cure rates are signiﬁ  cantly lower than in immunocompetent 
Table 2 Summary of reviewed studies on photodynamic therapy
Reference Treatment groups Number of lesions Regimen Results (at last follow-up) Follow-up
De Haas et al SI 25 ALA-PDT SI with 75 J/cm2 80% CR 12 months
2FI 25 ALA-PDT 2FI with 20 and 80 J/cm2 88% CR
Morton et al 1. MAL-PDT 275 lesions 111 treated 
with MAL-PDT
2x MAL-PDT (red-light) 1. 68% CR 24 months
2. Placebo-PDT 2. 11% CR
3. Cryotherapy 3. 59% CR
4. 5-FU 4. 60% CR
Morton et al ALA-PDT 20 1–2 × ALA-PDT 100% CR 12 months
Cryotherapy 20 1–3 × 20s FTC 90% CR
Salim et al ALA-PDT 33 1 × ALA-PDT 82% CR 12 months
5-FU 33 (red light) 48% CR
Morton et al ALA-PDT (green light) 29 green light (540 ± 15 nm, 62.6 J/cm2) 48% CR 12 months
ALA-PDT (red light) 32 red light (630 ± 15 nm, 125 J/cm2) 88% CR
Wong et al ALA-PDT 4 Light-emitting diode 630 ± 40 nm, 
240 J/cm2
75% CR after 1 treatment, 
1 recurrence after 8 months 
successful 2 treatment with 
CR after 20 months
16 months 
(20 months)
Dragieva et al ALA-PDT in OTR 4 1–2 ALA-PDT, incoherent light 
source (75 J/cm2)
50% CR 48 weeks
ALA-PDT in non-OTR 4 not speciﬁ  ed
Abbreviations: ALA, 5-aminolevulinic acid; CR, complete response; FTC, freeze-thaw cycles; ORT, organ transplant recipients; PDT, photodynamic therapy; SI, single 
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patients (Dragieva et al 2004), PDT is an excellent treatment 
option in transplant recipients because other standard 
therapies are limited in these patients as well.
Discussion
The conventional treatment options (cryotherapy, curettage 
with cautery, excision, 5-Fluorouracil, radiotherapy, laser) 
appear to have generally similar efﬁ  cacy and recurrence 
rates with no single therapy being superior for all clinical 
situations. They all have their advantages and they all are con-
nected with some certain side effects and adverse events (eg, 
ulceration, infection, scarring and hypopigmentation after 
cryotherapy; toxicity of radiotherapy and prolonged healing 
depending on the used technique; “fragile scalp syndrome” 
with atrophic epidermis and erosions after extensive carbon 
dioxide laser; inﬂ  ammation with erosion and ulceration 
during 5-FU).
As BD is often located on the lower limb of an older 
person, there is need for non-invasive treatment options with 
only mild-moderate local side effects or adverse events even 
in poor-healing sites.
Diclofenac 3% gel is a non-destructive therapy that was 
already successfully used in the treatment of actinic keratosis 
(Wolf et al 2001; Smith et al 2006).
In the seven published cases of BD treated with diclof-
enac 3% gel mentioned above the therapy was very effective 
(100% complete clinical and histological clearance) and it 
was well tolerated with only mild side effects (inﬂ  ammation, 
itching and dryness) (Pantel and Stockﬂ  eth 2007). However, 
these promising data have to be proven in randomized con-
trolled trials and optimum regimens (once vs twice daily 
application, duration of application, etc) and recurrence rates 
in long-term follow-up have to be investigated. Diclofenac 
3% gel is not yet licensed for BD.
The use of topical imiquimod is an effective alternative 
treatment option for patients and body sites that are unsuit-
able for other treatments like surgery.
As extragenital BD contains in about 47% of acral and 
in about 24% of nonacral lesions the HPV genome, imiqui-
mod might have a double effect in these cases because of its 
antiviral and antitumor activity through stimulation of innate 
and acquired immunity.
Nevertheless further and larger prospective studies 
with long-term follow-up are required to verify the results 
mentioned above and to figure out an optimal dosing 
scheme (duration of treatment, number of weekly applica-
tions) with high efﬁ  cacy and decreased local side effects 
(common local adverse effects: erythema, pruritus, erosion, 
ulceration vesicle formation). The risk of systemic side 
effects (eg, fever, ﬂ  u-like symptoms, lymphopenia) due 
to absorption of imiquimod has to be considered when 
imiquimod is used under occlusion. Imiquimod is not yet 
licensed for BD.
In comparative studies topical PDT had a similar efﬁ  cacy 
and less adverse events in comparison with cryotherapy and 
PDT was more effective with fewer adverse events when 
compared with 5-FU in the treatment of BD. The most 
common side effect during PDT is pain (reported by most 
of the patients as mild to moderate and by a minority as 
severe or even intolerable). Other common local side effects 
are erythema, edema and crust formation but in most of the 
studies no ulceration, infection or other more serious adverse 
events were seen.
Cosmetic outcome after PDT was typically superior com-
pared to the existing standard therapies. PDT can be repeated 
easily if required and it is popular with patients.
PDT is especially suited for poor-healing sites, patients 
with large and multiple lesions and patients with comor-
bidities (eg, diabetes, immunosupression, treatment with 
anticoagulants).
Another special group of patients proﬁ  ting from the 
(repetitive) treatment with PDT are immunosuppressed 
transplant recipients with their multiple premalignant and 
malignant cutaneous lesions and their higher risk to develop 
potentially fatal squamous cell carcinoma from AK and BD 
(although the evidence base in these patients is limited and 
the results showed a higher recurrence rate during follow-up 
compared with immunocompetent patients).
Thus there is no single definite “right way” for all 
patients with BD, the choice of treatment should be guided 
by its efﬁ  cacy, location and size of BD, number of lesions, 
availability of the therapy, the clinicians expertise, patient 
factors (age, immune status, concomitant medication, 
comorbidities and compliance), cosmetic outcome and the 
patients preference. In consideration of a 10% recurrence 
rate for most treatment options a risk-adapted follow-up is 
recommended.
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